Abstract
Background and Aims: Preeclampsia and intrahepatic cholestasis of pregnancy (ICP) are serious complications, which threaten mothers and fetuses with adverse outcomes such as stillbirth or preterm delivery. Labetalol, an alpha-/beta-adrenergic receptor antagonist is recommended in the therapy of hypertension in preeclampsia, however, the treatment was linked to drug-induced liver diseases and ICP. Therefore, we aimed to elucidate the effect of labetalol therapy on bile acid formation and metabolism in an animal model of ICP.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
